BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
PRODUCT EXPANSION

Continuing Efforts

BDSI is committed to pursuing clinical developments that bring new, meaningful therapies to patients living with serious and debilitating conditions.

Scroll down to see some of our latest initiatives.

Focused on launching pediatric clinical studies on ELYXYB™ (celecoxib oral solution) for the treatment of acute migraine

Exploring the potential of a new indication for ELYXYB for the treatment of acute pain

Further evaluating the expansion of ELYXYB into Canada

ELYXYB INDICATION AND USAGE

ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.

ELYXYB IMPORTANT SAFETY INFORMATION

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, 1-800-FDA-1088. Report an Adverse Event

Recent BDSI News

September 30, 2021

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty

Read more
September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 18, 2021BDSI $4.08/ - 1.75%
Data provided by Nasdaq. Minimum 15 minutes delayed.